Global Antiviral Therapeutics Technologies Market is expected to reach US$ 84.47Bn. at a CAGR of 6.31 during the forecast period 2029.Market Overview & Dynamics:
Antiviral therapy is one of the aspects of virology, since it has successfully employed basic science to generate very effective treatments for serious viral infections. Antiviral therapies have been developed against various viral diseases affecting humans like HIV, Hepatitis, Influenza and others. The sudden outbreak of the COVID-19 pandemic has made a strong impact on the global antiviral therapy market. With the development of this pandemic, the number of clinical studies on antiviral therapy, including remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir, ribavirin, arbidol, interferon, favipiravir and othrs has been increasing. However, the efficacy of these antiviral drugs for COVID-19 remains controversial. Remdesivir is the only Food and Drug Administration-approved drug for the treatment of COVID-19.To know about the Research Methodology :- Request Free Sample Report Rising prevalence of various viral diseases is expected to create new opportunities for development of new products and will drive the market growth. As per the news released on 3rd February 2021, 1126 clinical trials are going on for antiviral therapeutics. These trials are mainly driven by the growing burden of viral infections worldwide. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), approximately 38.0 million people globally were living with HIV in 2022. Moreover, strong research and development pipelines of the major players coupled with, increasing product launches, are of the key drivers in the antiviral therapeutics market growth. According to the recent data by Centers for Disease control and Prevention (CDC) in 2022, reported more than 38,000 new HIV infections in US. Many viral infections remain in the latent stage for a prolonged period and their diagnosis and treatment poses challenges Continuous efforts in the direction of research on antiviral therapies have improved the quality of life of patients suffering from viral infections. However, the appearance of newer viral infections worldwide and the emergence of multidrug-resistant strains and its transmission have put forward greater challenges to the clinical utility of antiviral therapies The report covers the detailed analysis of global Antiviral Therapeutics Technologies industry with the classifications of the market based on type, application and technology. Analysis of past market dynamics from 2018 to 2022 is given in the report, which will help readers to benchmark the past trends with current market scenarios with the key players contribution in it. The report has profiled sixteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the availability of advanced technology and new product launches are analyzed and report has come up with recommendations for future hot spot in APAC region.
Segment Analysis:
The global Antiviral Therapeutics Technologies market is segmented on the basis of product, application and technology. The product segment is divided into generic and branded drugs. The branded drugs segment held a dominant share in 2018 and is expected to continue the dominance throughout forecast period. The high availability of these branded drugs and high prescription and price rate is responsible for the segment growth. Based on application, the HIV/AIDS segment is expected to be the largest revenue holder during the forecast period. This is attributed due to large number of HIV patient pool present worldwide. For instance, as per the data published by UNAIDS, in 2017, around 37 million of the global population is living with HIV. The prevalence of HIV among the adults was estimated to be 0.8%. Therefore, increase in consumption of HIV anti-viral drugs for combating infection is the major factor that drives the growth of anti-viral therapies market for HIV segment. On the basis on technology segment, various technologies like gene therapy, antisense, RNAi and Nanotechnology are being applied for the treatment of viral infections. Amongst these technologies, the nanotechnology segment is anticipated to stimulate the market growth in upcoming years. With the advent of nanotechnology, it has been possible to comprehend the cellular mechanisms of the living cells and to develop relevant technologies which facilitate early diagnosis and treatment of various viral infections. Some of its applications consist of drug and gene delivery; use of fluorescent biological labels, detection of proteins, pathogens, and tumours; separation and purification of biological molecules and cells; tissue engineering; MRI contrast heightening; and pharmacokinetic studies. Thus, it has opened up a vast field of research and application with its ability to deal with viral diseases in an efficient manner and address the problems posed by traditional antiviral medicines. It has also helped to overcome the problems related to drug solubility and bioavailability.Regional Insights:
North America is expected to dominate the global market by holding a revenue share of xx% during forecast period. Growing prevalence of HIV and other viral infections in the region are expected to drive the market. For instance, as per the data published by CDC (Centre for Disease Control and Prevention), in 2022, the number of diagnoses of HIV infection in the U.S. were 38,281 (2017) and number of new hepatitis A, B, and C were 3,365, 3,409, and 4,225, respectively in 2018. Along with this, the growth of this region is mainly attributed due to increasing incestmetn in R&D and drug approval by FDA. In addition, to fuel the market growth in the current pandemic situation the federal government is providing support funds to pharmaceutical companies to help them to strengthen their clinical development pipelines. The report also helps in understanding Global Antiviral Therapeutics Technologies Market dynamics, structure by analyzing the market segments and project the Global Antiviral Therapeutics Technologies Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Antiviral Therapeutics Technologies Market make the report investor’s guide.Scope of the report: Inquire before Buying
Antiviral Therapeutics Technologies Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 55.04 Bn. Forecast Period 2023 to 2029 CAGR: 6.31% Market Size in 2029: US $ 84.47 Bn. Segments Covered: by Product Generic Drugs Branded Drugs by Application Hepatitis HIV/AIDS Herpes Influenza Others by Technology Gene therapy Antisense RNAi Nanotechnology Antiviral Therapeutics Technologies Market, by Region:
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest) South America (Brazil, Argetina and Rest of South America)Antiviral Therapeutics Technologies Market Key Players are:
1. Cipla 2. Gilead Sciences 3. F.Hoffmann-La Roche Ltd. 4. GlaxoSmithKline plc. 5. Bristol Myers Squibb 6. Aurobindo Pharma 7. Merck & Co. 8. Johnson & Johnson 9. AbbVie 10. Schering-Plough Corporation. 11. Abbott Laboratories 12. Novartis International AG 13. AstraZeneca 14. Cocrystal pharma 15. Daiichi Sankyo Co. Ltd. 16. Janssen Pharmaceuticals, Inc.Frequently Asked questions
1. What is the market size of the Global Antiviral Therapeutics Technologies Market in 2022? Ans. The market size Global Antiviral Therapeutics Technologies Market in 2022 was US$ 55.04 Billion. 2. What are the different segments of the Global Antiviral Therapeutics Technologies Market? Ans. The Global Antiviral Therapeutics Technologies Market is divided into Product, Application and Technology. 3. What is the study period of this market? Ans. The Global Antiviral Therapeutics Technologies Market will be studied from 2022 to 2029. 4. Which region is expected to hold the highest Global Antiviral Therapeutics Technologies Market share? Ans. The Asia Pacific dominates the market share in the market. 5. What is the Forecast Period of Global Antiviral Therapeutics Technologies Market? Ans. The Forecast Period of the market is 2023-2029 in the market.
Global Antiviral Therapeutics Technologies Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Analysis and Forecast 6.1. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Analysis and Forecast, By Product 7.1. Introduction and Definition 7.2. Key Findings 7.3. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Product 7.4. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Size (US$ Mn) Forecast, By Product 7.5. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Analysis, By Product 7.6. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Attractiveness Analysis, By Product 8. Global ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Analysis and Forecast, By Application 8.1. Introduction and Definition 8.2. Key Findings 8.3. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Application 8.4. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Size (US$ Mn) Forecast, By Application 8.5. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Analysis, By Application 8.6. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Attractiveness Analysis, By Application 9. Global ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Analysis and Forecast By Technology 9.1. Introduction and Definition 9.2. Key Findings 9.3. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Technology 9.4. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Size (US$ Mn) Forecast, By Technology 9.5. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Analysis, By Technology 9.6. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Attractiveness Analysis, By Technology 10. Global ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Analysis, By Region 10.1. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Region 10.2. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Size (US$ Mn) Forecast, By Region 10.3. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Attractiveness Analysis, By Region 11. North America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Analysis 11.1. Key Findings 11.2. North America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Overview 11.3. North America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Product 11.4. North America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 11.4.1. Generic Drugs 11.4.2. Branded Drugs 11.5. North America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Application 11.6. North America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 11.6.1. Hepatitis 11.6.2. HIV/AIDS 11.6.3. Herpes 11.6.4. Influenza 11.6.5. Others 11.7. North America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Technology 11.8. North America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 11.8.1. Gene therapy 11.8.2. Antisense 11.8.3. RNAi 11.8.4. Nanotechnology 11.9. North America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Country 11.10. North America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Country 11.10.1. U.S. 11.10.2. Canada 11.10.3. Mexico 11.11. North America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Analysis, By Country 11.12. U.S. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 11.12.1. Generic Drugs 11.12.2. Branded Drugs 11.13. U.S. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 11.13.1. Hepatitis 11.13.2. HIV/AIDS 11.13.3. Herpes 11.13.4. Influenza 11.13.5. Others 11.14. U.S. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 11.14.1. Gene therapy 11.14.2. Antisense 11.14.3. RNAi 11.14.4. Nanotechnology 11.15. Canada ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 11.15.1. Generic Drugs 11.15.2. Branded Drugs 11.16. Canada ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 11.16.1. Hepatitis 11.16.2. HIV/AIDS 11.16.3. Herpes 11.16.4. Influenza 11.16.5. Others 11.17. Canada ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 11.17.1. Gene therapy 11.17.2. Antisense 11.17.3. RNAi 11.17.4. Nanotechnology 11.18. Mexico ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 11.18.1. Generic Drugs 11.18.2. Branded Drugs 11.19. Mexico ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 11.19.1. Hepatitis 11.19.2. HIV/AIDS 11.19.3. Herpes 11.19.4. Influenza 11.19.5. Others 11.20. Mexico ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 11.20.1. Gene therapy 11.20.2. Antisense 11.20.3. RNAi 11.20.4. Nanotechnology 11.21. North America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Attractiveness Analysis 11.21.1. By Product 11.21.2. By Application 11.21.3. By Technology 11.22. PEST Analysis 11.23. Key Trends 11.24. Key Developments 12. Europe ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Analysis 12.1. Key Findings 12.2. Europe ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Overview 12.3. Europe ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Product 12.4. Europe ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 12.4.1. Generic Drugs 12.4.2. Branded Drugs 12.5. Europe ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Application 12.6. Europe ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 12.6.1. Hepatitis 12.6.2. HIV/AIDS 12.6.3. Herpes 12.6.4. Influenza 12.6.5. Others 12.7. Europe ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Technology 12.8. Europe ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 12.8.1. Gene therapy 12.8.2. Antisense 12.8.3. RNAi 12.8.4. Nanotechnology 12.9. Europe ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Country 12.10. Europe ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Sweden 12.10.7. CIS countries 12.10.8. Rest of Europe 12.11. Germany ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 12.11.1. Generic Drugs 12.11.2. Branded Drugs 12.12. Germany ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 12.12.1. Hepatitis 12.12.2. HIV/AIDS 12.12.3. Herpes 12.12.4. Influenza 12.12.5. Others 12.13. Germany ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 12.13.1. Gene therapy 12.13.2. Antisense 12.13.3. RNAi 12.13.4. Nanotechnology 12.14. U.K. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 12.14.1. Generic Drugs 12.14.2. Branded Drugs 12.15. U.K. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 12.15.1. Hepatitis 12.15.2. HIV/AIDS 12.15.3. Herpes 12.15.4. Influenza 12.15.5. Others 12.16. U.K. ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 12.16.1. Gene therapy 12.16.2. Antisense 12.16.3. RNAi 12.16.4. Nanotechnology 12.17. France ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 12.17.1. Generic Drugs 12.17.2. Branded Drugs 12.18. France ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 12.18.1. Hepatitis 12.18.2. HIV/AIDS 12.18.3. Herpes 12.18.4. Influenza 12.18.5. Others 12.19. France ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 12.19.1. Gene therapy 12.19.2. Antisense 12.19.3. RNAi 12.19.4. Nanotechnology 12.20. Italy ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 12.20.1. Generic Drugs 12.20.2. Branded Drugs 12.21. Italy ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 12.21.1. Hepatitis 12.21.2. HIV/AIDS 12.21.3. Herpes 12.21.4. Influenza 12.21.5. Others 12.22. Italy ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 12.22.1. Gene therapy 12.22.2. Antisense 12.22.3. RNAi 12.22.4. Nanotechnology 12.23. Spain ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 12.23.1. Generic Drugs 12.23.2. Branded Drugs 12.24. Spain ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 12.24.1. Hepatitis 12.24.2. HIV/AIDS 12.24.3. Herpes 12.24.4. Influenza 12.24.5. Others 12.25. Spain ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 12.25.1. Gene therapy 12.25.2. Antisense 12.25.3. RNAi 12.25.4. Nanotechnology 12.26. Sweden ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 12.26.1. Generic Drugs 12.26.2. Branded Drugs 12.27. Sweden ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 12.27.1. Hepatitis 12.27.2. HIV/AIDS 12.27.3. Herpes 12.27.4. Influenza 12.27.5. Others 12.28. Sweden ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 12.28.1. Gene therapy 12.28.2. Antisense 12.28.3. RNAi 12.28.4. Nanotechnology 12.29. CIS countries ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 12.29.1. Generic Drugs 12.29.2. Branded Drugs 12.30. CIS countries ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 12.30.1. Hepatitis 12.30.2. HIV/AIDS 12.30.3. Herpes 12.30.4. Influenza 12.30.5. Others 12.31. CIS countries ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 12.31.1. Gene therapy 12.31.2. Antisense 12.31.3. RNAi 12.31.4. Nanotechnology 12.32. Rest of Europe ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 12.32.1. Generic Drugs 12.32.2. Branded Drugs 12.33. Rest of Europe ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 12.33.1. Hepatitis 12.33.2. HIV/AIDS 12.33.3. Herpes 12.33.4. Influenza 12.33.5. Others 12.34. Rest of Europe ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 12.34.1. Gene therapy 12.34.2. Antisense 12.34.3. RNAi 12.34.4. Nanotechnology 12.35. Europe ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Attractiveness Analysis 12.35.1. By Application 12.35.2. By Product 12.35.3. By Technology 12.36. PEST Analysis 12.37. Key Trends 12.38. Key Developments 13. Asia Pacific ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Analysis 13.1. Key Findings 13.2. Asia Pacific ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Overview 13.3. Asia Pacific ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Product 13.4. Asia Pacific ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 13.4.1. Generic Drugs 13.4.2. Branded Drugs 13.5. Asia Pacific ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Application 13.6. Asia Pacific ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 13.6.1. Hepatitis 13.6.2. HIV/AIDS 13.6.3. Herpes 13.6.4. Influenza 13.6.5. Others 13.7. Asia Pacific ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Technology 13.8. Asia Pacific ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 13.8.1. Gene therapy 13.8.2. Antisense 13.8.3. RNAi 13.8.4. Nanotechnology 13.9. Asia Pacific ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Country 13.10. Asia Pacific ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. South Korea 13.10.5. Australia 13.10.6. ASEAN 13.10.7. Rest of Asia Pacific 13.11. Asia Pacific ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Analysis, By Country 13.12. China ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 13.12.1. Generic Drugs 13.12.2. Branded Drugs 13.13. China ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 13.13.1. Hepatitis 13.13.2. HIV/AIDS 13.13.3. Herpes 13.13.4. Influenza 13.13.5. Others 13.14. China ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 13.14.1. Gene therapy 13.14.2. Antisense 13.14.3. RNAi 13.14.4. Nanotechnology 13.15. India ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 13.15.1. Generic Drugs 13.15.2. Branded Drugs 13.16. India ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 13.16.1. Hepatitis 13.16.2. HIV/AIDS 13.16.3. Herpes 13.16.4. Influenza 13.16.5. Others 13.17. India ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 13.17.1. Gene therapy 13.17.2. Antisense 13.17.3. RNAi 13.17.4. Nanotechnology 13.18. Japan ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 13.18.1. Generic Drugs 13.18.2. Branded Drugs 13.19. Japan ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 13.19.1. Hepatitis 13.19.2. HIV/AIDS 13.19.3. Herpes 13.19.4. Influenza 13.19.5. Others 13.20. Japan ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 13.20.1. Gene therapy 13.20.2. Antisense 13.20.3. RNAi 13.20.4. Nanotechnology 13.21. South Korea ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 13.21.1. Generic Drugs 13.21.2. Branded Drugs 13.22. South Korea ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 13.22.1. Hepatitis 13.22.2. HIV/AIDS 13.22.3. Herpes 13.22.4. Influenza 13.22.5. Others 13.23. South Korea ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 13.23.1. Gene therapy 13.23.2. Antisense 13.23.3. RNAi 13.23.4. Nanotechnology 13.24. Australia ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 13.24.1. Generic Drugs 13.24.2. Branded Drugs 13.25. Australia ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 13.25.1. Hepatitis 13.25.2. HIV/AIDS 13.25.3. Herpes 13.25.4. Influenza 13.25.5. Others 13.26. Australia ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 13.26.1. Gene therapy 13.26.2. Antisense 13.26.3. RNAi 13.26.4. Nanotechnology 13.27. ASEAN ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 13.27.1. Generic Drugs 13.27.2. Branded Drugs 13.28. ASEAN ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 13.28.1. Hepatitis 13.28.2. HIV/AIDS 13.28.3. Herpes 13.28.4. Influenza 13.28.5. Others 13.29. ASEAN ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 13.29.1. Gene therapy 13.29.2. Antisense 13.29.3. RNAi 13.29.4. Nanotechnology 13.30. Rest of Asia Pacific ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 13.30.1. Generic Drugs 13.30.2. Branded Drugs 13.31. Rest of Asia Pacific ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 13.31.1. Hepatitis 13.31.2. HIV/AIDS 13.31.3. Herpes 13.31.4. Influenza 13.31.5. Others 13.32. Rest of Asia Pacific ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 13.32.1. Gene therapy 13.32.2. Antisense 13.32.3. RNAi 13.32.4. Nanotechnology 13.33. Asia Pacific ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Attractiveness Analysis 13.33.1. By Product 13.33.2. By Application 13.33.3. By Technology 13.34. PEST Analysis 13.35. Key Trends 13.36. Key Developments 14. Middle East & Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Analysis 14.1. Key Findings 14.2. Middle East & Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Overview 14.3. Middle East & Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Product 14.4. Middle East & Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 14.4.1. Generic Drugs 14.4.2. Branded Drugs 14.5. Middle East & Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Application 14.6. Middle East & Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 14.6.1. Hepatitis 14.6.2. HIV/AIDS 14.6.3. Herpes 14.6.4. Influenza 14.6.5. Others 14.7. Middle East & Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Technology 14.8. Middle East & Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 14.8.1. Gene therapy 14.8.2. Antisense 14.8.3. RNAi 14.8.4. Nanotechnology 14.9. Middle East & Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Country 14.10. Middle East & Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Country 14.10.1. GCC Countries 14.10.2. South Africa 14.10.3. Nigeria 14.10.4. Egypt 14.10.5. Rest of Middle East & Africa 14.11. Middle East & Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Analysis, By Country 14.12. GCC Countries ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 14.12.1. Generic Drugs 14.12.2. Branded Drugs 14.13. GCC Countries ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 14.13.1. Hepatitis 14.13.2. HIV/AIDS 14.13.3. Herpes 14.13.4. Influenza 14.13.5. Others 14.14. GCC Countries ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 14.14.1. Gene therapy 14.14.2. Antisense 14.14.3. RNAi 14.14.4. Nanotechnology 14.15. South Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 14.15.1. Generic Drugs 14.15.2. Branded Drugs 14.16. South Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 14.16.1. Hepatitis 14.16.2. HIV/AIDS 14.16.3. Herpes 14.16.4. Influenza 14.16.5. Others 14.17. South Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 14.17.1. Gene therapy 14.17.2. Antisense 14.17.3. RNAi 14.17.4. Nanotechnology 14.18. Nigeria ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 14.18.1. Generic Drugs 14.18.2. Branded Drugs 14.19. Nigeria ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 14.19.1. Hepatitis 14.19.2. HIV/AIDS 14.19.3. Herpes 14.19.4. Influenza 14.19.5. Others 14.20. Nigeria ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 14.20.1. Gene therapy 14.20.2. Antisense 14.20.3. RNAi 14.20.4. Nanotechnology 14.21. Egypt ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 14.21.1. Generic Drugs 14.21.2. Branded Drugs 14.22. Egypt ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 14.22.1. Hepatitis 14.22.2. HIV/AIDS 14.22.3. Herpes 14.22.4. Influenza 14.22.5. Others 14.23. Egypt ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 14.23.1. Gene therapy 14.23.2. Antisense 14.23.3. RNAi 14.23.4. Nanotechnology 14.24. Rest of Middle East & Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 14.24.1. Generic Drugs 14.24.2. Branded Drugs 14.25. Rest of Middle East & Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 14.25.1. Hepatitis 14.25.2. HIV/AIDS 14.25.3. Herpes 14.25.4. Influenza 14.25.5. Others 14.26. Rest of Middle East & Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 14.26.1. Gene therapy 14.26.2. Antisense 14.26.3. RNAi 14.26.4. Nanotechnology 14.27. Middle East & Africa ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Attractiveness Analysis 14.27.1. By Product 14.27.2. By Application 14.27.3. By Technology 14.28. PEST Analysis 14.29. Key Trends 14.30. Key Developments 15. South America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Analysis 15.1. Key Findings 15.2. South America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Overview 15.3. South America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Product 15.4. South America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 15.4.1. Generic Drugs 15.4.2. Branded Drugs 15.5. South America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Application 15.6. South America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 15.6.1. Hepatitis 15.6.2. HIV/AIDS 15.6.3. Herpes 15.6.4. Influenza 15.6.5. Others 15.7. South America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Technology 15.8. South America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 15.8.1. Gene therapy 15.8.2. Antisense 15.8.3. RNAi 15.8.4. Nanotechnology 15.9. South America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Value Share Analysis, By Country 15.10. South America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Country 15.10.1. Brazil 15.10.2. Colombia 15.10.3. Argentina 15.10.4. Rest of South America 15.11. South America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Analysis, By Country 15.12. Brazil ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 15.12.1. Generic Drugs 15.12.2. Branded Drugs 15.13. Brazil ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 15.13.1. Hepatitis 15.13.2. HIV/AIDS 15.13.3. Herpes 15.13.4. Influenza 15.13.5. Others 15.14. Brazil ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 15.14.1. Gene therapy 15.14.2. Antisense 15.14.3. RNAi 15.14.4. Nanotechnology 15.15. Colombia ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 15.15.1. Generic Drugs 15.15.2. Branded Drugs 15.16. Colombia ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 15.16.1. Hepatitis 15.16.2. HIV/AIDS 15.16.3. Herpes 15.16.4. Influenza 15.16.5. Others 15.17. Colombia ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 15.17.1. Gene therapy 15.17.2. Antisense 15.17.3. RNAi 15.17.4. Nanotechnology 15.18. Argentina ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 15.18.1. Generic Drugs 15.18.2. Branded Drugs 15.19. Argentina ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 15.19.1. Hepatitis 15.19.2. HIV/AIDS 15.19.3. Herpes 15.19.4. Influenza 15.19.5. Others 15.20. Argentina ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 15.20.1. Gene therapy 15.20.2. Antisense 15.20.3. RNAi 15.20.4. Nanotechnology 15.21. Rest of South America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Product 15.21.1. Generic Drugs 15.21.2. Branded Drugs 15.22. Rest of South America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Application 15.22.1. Hepatitis 15.22.2. HIV/AIDS 15.22.3. Herpes 15.22.4. Influenza 15.22.5. Others 15.23. Rest of South America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Forecast, By Technology 15.23.1. Gene therapy 15.23.2. Antisense 15.23.3. RNAi 15.23.4. Nanotechnology 15.24. South America ANTIVIRAL THERAPEUTICS TECHNOLOGIES Market Attractiveness Analysis 15.24.1. By Product 15.24.2. By Application 15.24.3. By Technology 15.25. PEST Analysis 15.26. Key Trends 15.27. Key Developments 16. Company Profiles 16.1. Market Share Analysis, By Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players By price, presence, market share, Application, and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A By Regions, Investment and Application 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Cipla 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Gilead Sciences 16.3.3. F.Hoffmann-La Roche Ltd. 16.3.4. GlaxoSmithKline plc. 16.3.5. Bristol Myers Squibb 16.3.6. Aurobindo Pharma 16.3.7. Merck & Co. 16.3.8. Johnson & Johnson 16.3.9. AbbVie 16.3.10. Schering-Plough Corporation. 16.3.11. Abbott Laboratories 16.3.12. Novartis International AG 16.3.13. AstraZeneca 16.3.14. Cocrystal pharma 16.3.15. Daiichi Sankyo Co. Ltd. 16.3.16. Janssen Pharmaceuticals, Inc. 17. Primary key Insights